Roche touts 2-year efficacy data for SMA therapy Evrysdi; NIH funds new network to study flu and viruses with ‘pandemic potential’
Two years after therapy, 61% of babies with spinal muscular atrophy Type 1 treated with Roche’s Evrysdi (risdiplam) were able to sit up without support …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
